Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I/II proof-of-concept study evaluating intramuscular injection of AT-982 in adult subjects with Pompe disease.

Trial Profile

A phase I/II proof-of-concept study evaluating intramuscular injection of AT-982 in adult subjects with Pompe disease.

Planning
Phase of Trial: Phase I/II

Latest Information Update: 07 Jan 2019

At a glance

  • Drugs AT 982 (Primary)
  • Indications Glycogen storage disease type II
  • Focus Adverse reactions; Proof of concept
  • Most Recent Events

    • 07 Jan 2019 According to an Audentes Therapeutics media release, company is planning to file IND in the third quarter of 2019.
    • 06 Feb 2018 According to an Audentes Therapeutics media release, the company plans to file an IND for AT982 in the second quarter of 2018 and plans to initiate a Phase 1/2 clinical study in the fourth quarter of 2018.
    • 19 May 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top